169 related articles for article (PubMed ID: 34862210)
1. Validation of Genetic Markers Associated with Survival in Colorectal Cancer Patients Treated with Oxaliplatin-Based Chemotherapy.
Park HA; Seibold P; Edelmann D; Benner A; Canzian F; Alwers E; Jansen L; Schneider M; Hoffmeister M; Brenner H; Chang-Claude J
Cancer Epidemiol Biomarkers Prev; 2022 Feb; 31(2):352-361. PubMed ID: 34862210
[TBL] [Abstract][Full Text] [Related]
2. SNPs in transporter and metabolizing genes as predictive markers for oxaliplatin treatment in colorectal cancer patients.
Kap EJ; Seibold P; Scherer D; Habermann N; Balavarca Y; Jansen L; Zucknick M; Becker N; Hoffmeister M; Ulrich A; Benner A; Ulrich CM; Burwinkel B; Brenner H; Chang-Claude J
Int J Cancer; 2016 Jun; 138(12):2993-3001. PubMed ID: 26835885
[TBL] [Abstract][Full Text] [Related]
3. Genetic variants in DNA repair genes as potential predictive markers for oxaliplatin chemotherapy in colorectal cancer.
Kap EJ; Seibold P; Richter S; Scherer D; Habermann N; Balavarca Y; Jansen L; Becker N; Pfütze K; Popanda O; Hoffmeister M; Ulrich A; Benner A; Ulrich CM; Burwinkel B; Brenner H; Chang-Claude J
Pharmacogenomics J; 2015 Dec; 15(6):505-12. PubMed ID: 25778469
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers?
Fariña Sarasqueta A; van Lijnschoten G; Lemmens VE; Rutten HJ; van den Brule AJ
Mol Diagn Ther; 2011 Oct; 15(5):277-83. PubMed ID: 21958378
[TBL] [Abstract][Full Text] [Related]
5. Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival.
Salimzadeh H; Lindskog EB; Gustavsson B; Wettergren Y; Ljungman D
BMC Cancer; 2020 May; 20(1):409. PubMed ID: 32397974
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer.
Suenaga M; Schirripa M; Cao S; Zhang W; Cremolini C; Lonardi S; Okazaki S; Berger MD; Miyamoto Y; Soni S; Barzi A; Yamaguchi T; Loupakis F; Falcone A; Lenz HJ
Pharmacogenomics J; 2021 Jun; 21(3):285-295. PubMed ID: 33542444
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide study of genetic polymorphisms predictive for outcome from first-line oxaliplatin-based chemotherapy in colorectal cancer patients.
Park HA; Edelmann D; Canzian F; Seibold P; Harrison TA; Hua X; Shi Q; Silverman A; Benner A; Macauda A; Schneider M; Goldberg RM; Alberts SR; Hoffmeister M; Brenner H; Chan AT; Peters U; Newcomb PA; Chang-Claude J
Int J Cancer; 2023 Nov; 153(9):1623-1634. PubMed ID: 37539667
[TBL] [Abstract][Full Text] [Related]
8. ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt.
Kassem AB; Salem SE; Abdelrahim ME; Said AS; Salahuddin A; Hussein MM; Bahnassy AA
Exp Mol Pathol; 2017 Feb; 102(1):78-85. PubMed ID: 28088319
[TBL] [Abstract][Full Text] [Related]
9. Functional Analysis of SNPs in the ERCC5 Promoter in Advanced Colorectal Cancer Patients Treated With Oxaliplatin-Based Chemotherapy.
Chen J; Luo X; Xie G; Chen K; Jiang H; Pan F; Li J; Ruan Z; Pang X; Liang H
Medicine (Baltimore); 2016 May; 95(19):e3652. PubMed ID: 27175691
[TBL] [Abstract][Full Text] [Related]
10. Influence of ABCB-1, ERCC-1 and ERCC-2 gene polymorphisms on response to capecitabine and oxaliplatin (CAPOX) treatment in colorectal cancer (CRC) patients of South India.
Varma A; Mathaiyan J; Shewade D; Dubashi B; Sunitha K
J Clin Pharm Ther; 2020 Aug; 45(4):617-627. PubMed ID: 32399998
[TBL] [Abstract][Full Text] [Related]
11. AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin.
Kjersem JB; Thomsen M; Guren T; Hamfjord J; Carlsson G; Gustavsson B; Ikdahl T; Indrebø G; Pfeiffer P; Lingjærde O; Tveit KM; Wettergren Y; Kure EH
Pharmacogenomics J; 2016 Jun; 16(3):272-9. PubMed ID: 26261061
[TBL] [Abstract][Full Text] [Related]
12. Pattern Recognition Receptor Polymorphisms as Predictors of Oxaliplatin Benefit in Colorectal Cancer.
Gray V; Briggs S; Palles C; Jaeger E; Iveson T; Kerr R; Saunders MP; Paul J; Harkin A; McQueen J; Summers MG; Johnstone E; Wang H; Gatcombe L; Maughan TS; Kaplan R; Escott-Price V; Al-Tassan NA; Meyer BF; Wakil SM; Houlston RS; Cheadle JP; Tomlinson I; Church DN
J Natl Cancer Inst; 2019 Aug; 111(8):828-836. PubMed ID: 30649440
[TBL] [Abstract][Full Text] [Related]
13. Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.
Loupakis F; Cremolini C; Yang D; Salvatore L; Zhang W; Wakatsuki T; Bohanes P; Schirripa M; Benhaim L; Lonardi S; Antoniotti C; Aprile G; Graziano F; Ruzzo A; Lucchesi S; Ronzoni M; De Vita F; Tonini G; Falcone A; Lenz HJ
PLoS One; 2013; 8(7):e66774. PubMed ID: 23861747
[TBL] [Abstract][Full Text] [Related]
14. Relationship between the Asp1104His polymorphism of the nucleotide excision repair gene ERCC5 and treatment sensitivity to oxaliplatin in patients with advanced colorectal cancer in China.
Kong J; Liu Z; Cai F; Xu X; LiuI J
Clinics (Sao Paulo); 2018 Dec; 73():e455. PubMed ID: 30517302
[TBL] [Abstract][Full Text] [Related]
15. Genetic variants in RPA1 associated with the response to oxaliplatin-based chemotherapy in colorectal cancer.
Li S; Xu K; Gu D; He L; Xie L; Chen Z; Fan Z; Zhu L; Du M; Chu H; Zhang Z; Wu Y; Ni M; Wang M
J Gastroenterol; 2019 Nov; 54(11):939-949. PubMed ID: 30923916
[TBL] [Abstract][Full Text] [Related]
16. Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer.
Abraham JP; Magee D; Cremolini C; Antoniotti C; Halbert DD; Xiu J; Stafford P; Berry DA; Oberley MJ; Shields AF; Marshall JL; Salem ME; Falcone A; Grothey A; Hall MJ; Venook AP; Lenz HJ; Helmstetter A; Korn WM; Spetzler DB
Clin Cancer Res; 2021 Feb; 27(4):1174-1183. PubMed ID: 33293373
[TBL] [Abstract][Full Text] [Related]
17. Predictive Polygenic Score for Outcome after First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients Using Supervised Principal Component Analysis.
Park HA; Edelmann D; Canzian F; Harrison TA; Hua X; Shi Q; Silverman A; Schneider M; Goldberg RM; Alberts SR; Hoffmeister M; Brenner H; Chan AT; Peters U; Newcomb PA; Chang-Claude J
Cancer Epidemiol Biomarkers Prev; 2022 Nov; 31(11):2087-2091. PubMed ID: 35984985
[TBL] [Abstract][Full Text] [Related]
18. Genetic variants in the glutathione S-transferase genes and survival in colorectal cancer patients after chemotherapy and differences according to treatment with oxaliplatin.
Kap EJ; Richter S; Rudolph A; Jansen L; Ulrich A; Hoffmeister M; Ulrich CM; Brenner H; Chang-Claude J
Pharmacogenet Genomics; 2014 Jul; 24(7):340-7. PubMed ID: 24842074
[TBL] [Abstract][Full Text] [Related]
19. ERCC1 and XPD/ERCC2 polymorphisms' predictive value of oxaliplatin-based chemotherapies in advanced colorectal cancer has an ethnic discrepancy: a meta-analysis.
Lu X; Xiao S; Jin C; van der Straaten T; Li X
J Clin Lab Anal; 2012 Jan; 26(1):10-5. PubMed ID: 24833529
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of colorectal cancer-risk loci and survival outcome: A prognostic role for CDH1 variants.
Summers MG; Maughan TS; Kaplan R; Law PJ; Houlston RS; Escott-Price V; Cheadle JP
Eur J Cancer; 2020 Jan; 124():56-63. PubMed ID: 31734605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
